Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.